沙格列汀对SAVOR-TIMI 53试验中肾脏结局的影响
SAVOR-TIMI 53试验纳入16,492例2型糖尿病患者,随机接受沙格列汀或安慰剂,中位随访2.1年。沙格列汀与尿白蛋白/肌酐比值(ACR)分类改善和/或恶化减少相关,且不依赖血糖控制, estimated glomerular filtration rate(eGFR)变化与安慰剂组相似。
要点
- 沙格列汀改善ACR,即使在正常白蛋白尿范围也可见。
- ACR变化与HbA1c变化不相关(r=0.041、0.052、0.036)。
- 沙格列汀组与安慰剂组eGFR变化及肾脏安全结局相似。
核心结论
- 沙格列汀改善ACR,即使在正常白蛋白尿范围也有效,且不影响eGFR;其对白蛋白尿的益处不能由其降糖作用解释。
研究设计与样本
- SAVOR-TIMI 53试验的肾脏结局分析,16,492例2型糖尿病患者随机接受沙格列汀或安慰剂,中位随访2.1年。
主要发现
- 基线时9,696例(58.8%)为正常白蛋白尿(ACR<30 mg/g),4,426例(26.8%)为微量白蛋白尿(ACR 30-300 mg/g),1,638例(9.9%)为大量白蛋白尿(ACR>300 mg/g)。
- 沙格列汀与基线至试验结束时ACR分类改善和/或恶化减少相关(基线正常白蛋白尿、微量白蛋白尿、大量白蛋白尿个体P值分别为0.021、P<0.001、P=0.049)。
- 2年时,沙格列汀组与安慰剂组平均ACR变化差异:eGFR>50 mL/min/BSA为-19.3 mg/g(P=0.033),50≥eGFR≥30 mL/min/BSA为-105 mg/g(P=0.011),eGFR<30 mL/min/BSA为-245.2 mg/g(P=0.086)。
- 将ACR作为连续变量分析显示沙格列汀组ACR降低(1年P<0.0001;2年P=0.0143;试验结束时P=0.0158)。
- ACR变化与HbA1c变化不相关(r=0.041、0.052、0.036;分别为1年、2年、试验结束时)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Dipeptidyl peptidase 4 inhibitors may have a protective effect in diabetic nephropathy. RESEARCH DESIGN AND METHODS: We studied renal outcomes of 16,492 patients with type 2 diabetes, randomized to saxagliptin versus placebo and followed for a median of 2.1 years in the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus-Thrombolysis in Myocardial Infarction 53 (SAVOR-TIMI 53) trial. RESULTS: At baseline, 9,696 (58.8%) subjects had normoalbuminuria (albumin/creatinine ratio [ACR] <30 mg/g), 4,426 (26.8%) had microalbuminuria (ACR 30-300 mg/g), and 1,638 (9.9%) had macroalbuminuria (ACR >300 mg/g). Treatment with saxagliptin was associated with improvement in and/or less deterioration in ACR categories from baseline to end of trial (EOT) (P = 0.021, P < 0.001, and P = 0.049 for individuals with baseline normoalbuminuria, microalbuminuria, and macroalbuminuria, respectively). At 2 years, the difference in mean ACR change between saxagliptin and placebo arms was -19.3 mg/g (P = 0.033) for estimated glomerular filtration rate (eGFR) >50 mL/min/body surface area per 1.73 m2 (BSA), -105 mg/g (P = 0.011) for 50 ≥ eGFR ≥ 30 mL/min/BSA, and -245.2 mg/g (P = 0.086) for eGFR <30 mL/min/BSA. Analyzing ACR as a continuous variable showed reduction in ACR with saxagliptin (1 year, P < 0.0001; 2 years, P = 0.0143; and EOT, P = 0.0158). The change in ACR did not correlate with that in HbA1c (r = 0.041, 0.052, and 0.036; 1 year, 2 years, and EOT, respectively). The change in eGFR was similar in the saxagliptin and placebo groups. Safety renal outcomes, including doubling of serum creatinine, initiation of chronic dialysis, renal transplantation, or serum creatinine >6.0 mg/dL, were similar as well. CONCLUSIONS: Treatment with saxagliptin improved ACR, even in the normoalbuminuric range, without affecting eGFR. The beneficial effect of saxagliptin on albuminuria could not be explained by its effect on glycemic control.
引用
- Mosenzon O, Leibowitz G, Bhatt DL, et al. Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial. Diabetes Care. 2016. PMID: 27797925. doi:10.2337/dc16-0621
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。